BioInvent International AB (LTS:0H22) EBIT: kr-350.2 Mil (TTM As of Mar. 2026)


LTS:0H22 BioInvent International AB LTS:0H22
48 GF Score
Price kr23.63
GF Value kr48.64
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB EBIT?

BioInvent International AB LTS:0H22 -0.21% 48 EBIT is kr-350.2 Mil as of Mar. 2026. GuruFocus rates LTS:0H22 with a GF Score™ of 48/100 and a GF Value™ of kr48.64 (Possible Value Trap). The stock has 4 warning signs investors should review.

BioInvent International AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-121.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-350.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioInvent International AB's annualized ROC % for the quarter that ended in Mar. 2026 was -446.94%. BioInvent International AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,552.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioInvent International AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -30.74%.

BioInvent International AB  (LTS:0H22) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioInvent International AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-487.108 * ( 1 - 0% )/( (93.597 + 124.38)/ 2 )
=-487.108/108.9885
=-446.94 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=671.202 - 52.342 - ( 592.748 - max(0, 112.43 - 637.693+592.748))
=93.597

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=534.96 - 0 - ( 456.476 - max(0, 95.121 - 505.701+456.476))
=124.38

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

BioInvent International AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-487.108/( ( (33.509 + max(-76.831, 0)) + (29.259 + max(-40.374, 0)) )/ 2 )
=-487.108/( ( 33.509 + 29.259 )/ 2 )
=-487.108/31.384
=-1,552.09 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.685 + 12.292 + 14.252) - (52.342 + 0 + 52.718)
=-76.831

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(37.746 + 11.479 + 0) - (0 + 0 + 89.599)
=-40.374

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioInvent International AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-350.166/1138.954
=-30.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB EBIT Related Terms

BioInvent International AB EBIT Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB EBIT Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -277.93 -41.85 -329.46 -428.69 -332.06

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -122.79 34.13 -133.10 -129.41 -121.78

LTS:0H22 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, BioInvent International AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's EV-to-EBIT falls into.


LTS:0H22
48GF Score
BioInvent International AB LTS:0H22
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-350.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-350.2 Mil mean?
BioInvent International AB (LTS:0H22) has a EBIT of kr-350.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioInvent International AB.
Is BioInvent International AB's EBIT too high?
BioInvent International AB's current EBIT is kr-350.2 Mil. Overall, BioInvent International AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's EBIT compare to VRTX and REGN?
BioInvent International AB's EBIT of kr-350.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BioInvent International AB. BioInvent International AB's current EBIT is kr-350.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (LTS:0H22) is currently considered Possible Value Trap. The stock's GF Value™ is kr48.64, compared to a current price of kr23.63 — trading 51.4% below its estimated fair value. The current EBIT is kr-350.2 Mil. BioInvent International AB's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BioInvent International AB (LTS:0H22), the current EBIT is kr-350.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (LTS:0H22) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr23.63 is trading 51.4% below its estimated GF Value™ of kr48.64. GuruFocus considers BioInvent International AB to be Possible Value Trap.

Key valuation signals for LTS:0H22:

  • EBIT: kr-350.2 Mil
  • GF Value™: kr48.64 vs. price of kr23.63 (51.4% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Other Exchanges BINV:SwedenBIX:Germany
Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
48GF Score

Get the complete analysis for LTS:0H22

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.63
Price
kr48.64
GF Value